M. Piccini, G. Gianfaldoni, F. Mannelli, B. Scappini, Gaia Ciolli, Andrea Pasquini, Laura Fasano, S. Pilerci, E. Quinti, F. Crupi, P. Guglielmelli, A. Vannucchi
{"title":"AML-284 Venetoclax联合低甲基化药物或低剂量阿糖胞苷治疗复发/难治性npm1突变的急性髓系白血病:来自现实环境的临床经验","authors":"M. Piccini, G. Gianfaldoni, F. Mannelli, B. Scappini, Gaia Ciolli, Andrea Pasquini, Laura Fasano, S. Pilerci, E. Quinti, F. Crupi, P. Guglielmelli, A. Vannucchi","doi":"10.1016/s2152-2650(23)01030-3","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":10370,"journal":{"name":"Clinical Lymphoma Myeloma and Leukemia","volume":"19 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"AML-284 Venetoclax in Combination With Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia: Clinical Experience From a Real-Life Setting\",\"authors\":\"M. Piccini, G. Gianfaldoni, F. Mannelli, B. Scappini, Gaia Ciolli, Andrea Pasquini, Laura Fasano, S. Pilerci, E. Quinti, F. Crupi, P. Guglielmelli, A. Vannucchi\",\"doi\":\"10.1016/s2152-2650(23)01030-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":10370,\"journal\":{\"name\":\"Clinical Lymphoma Myeloma and Leukemia\",\"volume\":\"19 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Lymphoma Myeloma and Leukemia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s2152-2650(23)01030-3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma Myeloma and Leukemia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s2152-2650(23)01030-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
AML-284 Venetoclax in Combination With Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia: Clinical Experience From a Real-Life Setting